OncLive Staff

Articles

Rosenthal Discusses the Need for Standardized Care in AYA Hodgkin Lymphoma

February 2nd 2023

Dr Rosenthal discusses the care of adolescent and young adult patients with Hodgkin lymphoma, the discrepancies between pediatric and adult oncologists that result in differing treatment approaches, and common concerns these patients have as they navigate their diagnosis and treatment alongside other life changes.

Nair Notes the Benefits of Yoga as a Complementary Therapy in Nonmetastatic Breast Cancer

January 30th 2023

Dr Nair discusses a study evaluating the role of yoga as a complementary therapy in patients with breast cancer, how these results emphasize the importance of multidisciplinary breast cancer care, and the potential applications of these findings beyond breast cancer.

Further Study and Tailored Treatments Remain Unmet Needs in Male Breast Cancer

January 30th 2023

Jose Pablo Leone, MD, discusses the distinguishing features of male breast cancer, explains the benefits and limitations of current treatments, and emphasizes the importance of raising awareness about this breast cancer subset to propel further research.

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

January 26th 2023

Dr Shore discusses the FDA approval of nadofaragene firadenovec in non–muscle invasive bladder cancer, the benefits of this therapy’s administration method and schedule, and how this agent’s efficacy and safety pave the way for future treatment advances.

Practices Should Redouble Efforts to Help Patients Address Financial Toxicity

January 25th 2023

Although fully addressing the financial hardship of patients with cancer requires a complex, multifaceted approach, even small changes may ease these burdens and improve patient outcomes.

Goetz and Choong Describe the Need for Adjuvant Endocrine Therapy in ER-positive Breast Cancer

January 23rd 2023

Drs Goetz and Choong discuss the potential for adjuvant endocrine therapy omission in patients with estrogen receptor–positive breast cancer who have a pathologic complete response to neoadjuvant chemotherapy.

Experts Contextualize ASH Findings for Clinical Practice

January 23rd 2023

Data presented during the 2022 ASH Annual Meeting and Exposition showcased practice-changing updates from several studies across hematologic malignancies. Experts across hematologic cancers were on hand to discuss long-term readouts, the introduction of novel regimens for several diseases, and the impact of new data and trends in care for patients.

Dy Discusses CEACAM5-Directed and Other Second-Line Treatment Strategies in NSCLC

January 19th 2023

Dr Dy discusses the development of CEACAM5-directed antibody-drug conjugates in non–small cell lung cancer, ongoing research with tusamitamab ravtansine, and the potential role of competing docetaxel-based combination strategies in the second-line setting.

Giacchetti Discusses the Convergence of Chronobiology and Oncologic Care in Breast Cancer

January 16th 2023

Dr Giacchetti discusses the findings from a study of patient-selected timing of the daily oral intake of adjuvant hormone therapy and everolimus in breast cancer and how this study highlights the need for further research combining the fields of chronobiology and oncology.

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

January 12th 2023

Dr Hilal discusses data with frontline ibrutinib, acalabrutinib, and zanubrutinib in chronic lymphocytic leukemia; remaining uncertainties regarding the use of BTK inhibitors to manage this disease; and how a patient’s minimal residual disease status influences their subsequent treatment options.

Camidge and Cetnar Consider the Value of Career Scholarship, Leadership, and Mentorship

January 9th 2023

In the inaugural episode of ‘How This is Building Me,’ Camidge sits down with Cetnar to discuss the ins-and-outs of defining personal and professional success, perceptions around sought-after accolades and accomplishments, the meaning behind mentoring, and more.

Breast Cancer Advances in 2022 Showcase a Shifting Landscape

January 6th 2023

Joseph A. Sparano, MD, highlights practice-changing clinical trials, novel therapies, the evolving treatment landscape, and unmet needs in the field of breast cancer.

Breast Cancer Experts Review HR+ Treatment Updates From SABCS 2022

January 5th 2023

Drs Lu, Neven, Jacot, Medford, and Spring highlight updates in the treatment of hormone receptor–positive breast cancer that were presented at the 2022 San Antonio Breast Cancer Symposium.

Oppong Emphasizes How Patient Education Can Lower Breast Cancer Surgery Refusal Rates

January 2nd 2023

Dr Oppong discusses findings showing that Black and Hispanic women are more likely than their White counterparts to refuse surgery for nonmetastatic breast cancer, the reasons some patients refuse to undergo surgery, and potential strategies to overcome those objections.

Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors

December 29th 2022

Dr Somaiah discusses the excitement surrounding novel agents such as CSF1R inhibitors and ULK1/2 inhibitors, and the utility of broad spectrum TKIs such as ripretinib.

Rugo Summarizes Developments With Ribociclib and ADCs in HR-Positive Breast Cancer

December 26th 2022

Dr Rugo discusses overall survival in the TROPiCS-02 trial, post-progression treatments after ribociclib and endocrine therapy in the MONALEESA-2, MONALEESA-3, and MONALEESA-7 studies, and what the AMALEE trial indicates about optimal doses of ribociclib in hormone receptor–positive breast cancer.

Expert and Patient Perspectives on Comprehensive Multiple Myeloma Treatment

December 22nd 2022

Dr Kumar, Dr Patel, Falbo, and Ahlstrom highlight the importance of community-based discussions regarding adverse effects in multiple myeloma, the benefits of considering the whole treatment course, and subgroup analyses from the MAIA trial.

Blum Highlights Implications of CA-125 Levels in Renal Medullary Carcinoma

December 19th 2022

Dr Blum discusses renal medullary carcinoma, the lack of approved systemic therapy for these patients, and findings showing a correlation between CA-125 levels and increased tumor burden and treatment response in this disease.

FDA Approval Insights: Tremelimumab Plus Durvalumab and Chemotherapy in NSCLC

December 15th 2022

Dr Johnson discusses the FDA approval of tremelimumab plus durvalumab and chemotherapy in non–small cell lung cancer, key data from the POSEIDON trial, and the combination’s efficacy and tolerability in various patient populations.

Acuna Discusses US Liver Cancer Incidence in Individuals of Mexican Descent

December 12th 2022

Nicholas Acuna discusses research showing that incidence of liver cancer increases over time in people of Mexican descent living in Los Angeles, the “Latino paradox” in health outcomes, and the next steps for this research.